Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
复制标题
DOI：
10.1021/ic401211u
复制
发表时间：
2013-11-04
影响因子：
4.6
通讯作者：
O'Halloran TV
中科院分区：
文献类型：
--
作者：
Swindell EP;Hankins PL;Chen H;Miodragović DU;O'Halloran TV
从古代中国和希腊开始，含砷化合物用于治疗疾病已有3000多年的历史。它们在世纪被用于治疗各种疾病，包括寄生虫病和性传播疾病。人们对砷剂治疗应用的兴趣重新抬头，是因为发现低剂量的1%三氧化二砷水溶液（即亚砷酸）可完全缓解某些类型的白血病。自2000年FDA批准三氧化二砷（As2O3）用于治疗急性早幼粒细胞白血病（APL）以来，它已成为该适应症的一线治疗药物。目前有100多个涉及无机砷或有机砷化合物的临床试验在FDA注册用于治疗癌症。正在开发具有增强活性或靶向细胞毒性的新一代无机和有机金属砷化合物，以克服砷治疗剂的一些缺点，即血浆半衰期短和治疗窗窄。
Starting in ancient China and Greece, arsenic-containing compounds have been used in the treatment of disease for over 3000 years. They were used for a variety of diseases in the 20th century, including parasitic and sexually transmitted illnesses. A resurgence of interest in the therapeutic application of arsenicals has been driven by the discovery that low doses of a 1% aqueous solution of arsenic trioxide (i.e. arsenous acid) leads to complete remission of certain types of leukemia. Since FDA approval of arsenic trioxide (As2O3) for treatment of acute promyelocytic leukemia (APL) in 2000, it has become a front line therapy in this indication. There are currently over 100 active clinical trials involving inorganic arsenic or organoarsenic compounds registered with the FDA for the treatment of cancers. New generations of inorganic and organometallic arsenic compounds with enhanced activity or targeted cytotoxicity are being developed to overcome some of the shortcomings of arsenic therapeutics, namely short plasma half-lives and narrow therapeutic window.
登录
查看更多内容
影响因子：
11.5
作者：
Ardalan, Bach;Subbarayan, Pochi R.;Ganjei-Azar, Parvin
通讯作者：
Ganjei-Azar, Parvin
影响因子：
5.7
作者：
Chen H;Ahn R;Van den Bossche J;Thompson DH;O'Halloran TV
通讯作者：
O'Halloran TV
DOI：
10.1038/jes.2008.32
发表时间：
2009-01-01
影响因子：
4.5
作者：
Caldwell, Kathleen L.;Jones, Robert L.;Osterloh, John D.
通讯作者：
Osterloh, John D.
影响因子：
6.5
作者：
Berenson, James R.;Boccia, Ralph;Swift, Regina A.
通讯作者：
Swift, Regina A.
影响因子：
105.7
作者：
CROWTHER, D;POWLES, RL;SCOTT, RB
通讯作者：
SCOTT, RB